Morning vs random scheduling of Keytruda in advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study compares getting your standard pembrolizumab (Keytruda) infusion in the morning versus at different times of day. It tests whether the timing of your treatment influences how well it works or how you feel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (metastatic) non-small cell lung cancer with a high PDL1 score (at least 50%)
- You are a candidate for pembrolizumab (Keytruda) as your only cancer treatment (no other drugs, radiation, or surgery during the first 6 cycles)
- You are 18 years or older
- You are physically able to do most normal activities (ECOG score 0–2)
- If you could become pregnant, you agree to use highly effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the time of day you receive immunotherapy (in the morning vs. later) affects how well it works. It is for people with advanced lung cancer or other solid tumors who are just starting or continuing PD-1/PD-L1 inhibitor treatment.
This trial tests whether the time of day you receive your infusion (morning vs. afternoon) affects how well your cancer treatment works. It is for people with advanced lung cancer or head and neck cancer that can be surgically removed.
This trial is testing whether the time of day you receive chemotherapy and pembrolizumab (immunotherapy) affects how well they work against triple-negative breast cancer. It's for people who will get these treatments before surgery.
This trial looks at how the timing of pembrolizumab (an immunotherapy) infusions affects how well it works against triple-negative breast cancer when given before surgery along with chemotherapy. The goal is to learn if giving the infusion at a certain time of day improves treatment results.
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
Hear when a new Metastatic Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.